title: Enhanced thrombolysis induced by argatroban or activated protein C in the presence or absence of staphylokinase, measured in an in vivo animal model using mesenteric arterioles.
abstract: Successful administration of thrombolytic agents is associated with vessel reocclusion in a high proportion of cases. We have previously established an animal model to investigate platelet-rich thrombolytic mechanisms in vivo and demonstrated that recombinant staphylokinase (rSAK)-induced thrombolysis was enhanced by the concomitant administration of the direct thrombin inhibitor argatroban. The present study expanded the use of this model by comparing arterial and venous thrombolysis using advanced image analysis software. Mural thrombi were formed by Helium-Neon laser irradiation in mesenteric arterioles and were shown to be lysed, dose-dependently, by smaller amounts of rSAK than those required in venules. Activated protein C (APC), as well as argatroban, enhanced the rSAK-induced thrombolysis. APC or argatroban also induced thrombolysis in the absence of rSAK, and the effect was inhibited by tranexamic acid. The enhanced thrombolysis induced by APC or argatroban in the presence or absence of rSAK may be due to increased endogenous thrombolysis mediated by the inhibition of thrombin activity or delayed thrombin generation.
authors.affiliation: Laboratory of Physiology, Faculty of Nutrition, Kobe Gakuin University, Nishi-ku, Kobe 651-2180, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Hashimoto
authors.forename: S
authors.initials: S
authors.lastname: Watanabe
authors.forename: K
authors.initials: K
authors.lastname: Oiwa
authors.forename: Y
authors.initials: Y
authors.lastname: Ohta
authors.forename: T
authors.initials: T
authors.lastname: Kishi
authors.forename: T
authors.initials: T
authors.lastname: Okamoto
authors.forename: J C
authors.initials: JC
authors.lastname: Giddings
authors.forename: J
authors.initials: J
authors.lastname: Yamamoto
mesh_terms: D000818:Animals; D001120:Arginine / Q000031:analogs & derivatives; D001160:Arterioles; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D007091:Image Processing, Computer-Assisted / Q000379:methods; D007700:Kinetics; D007834:Lasers; D008297:Male; D008666:Metalloendopeptidases / Q000008:administration & dosage / Q000494:pharmacology; D010875:Pipecolic Acids / Q000008:administration & dosage / Q000494:pharmacology; D010960:Plasminogen Activators / Q000494:pharmacology; D011486:Protein C / Q000008:administration & dosage / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D013152:Splanchnic Circulation; D013449:Sulfonamides; D015912:Thrombolytic Therapy / Q000379:methods*; D013927:Thrombosis / Q000188:drug therapy / Q000473:pathology
chemical_list: D005343:Fibrinolytic Agents; D010875:Pipecolic Acids; D011486:Protein C; D013449:Sulfonamides; D001120:Arginine; D010960:Plasminogen Activators; D008666:Metalloendopeptidases; C022653:auR protein, Staphylococcus aureus; C031942:argatroban